247 related articles for article (PubMed ID: 24329153)
1. Choosing treatment options for patients with relapsed/refractory multiple myeloma.
Castelli R; Orofino N; Losurdo A; Gualtierotti R; Cugno M
Expert Rev Anticancer Ther; 2014 Feb; 14(2):199-215. PubMed ID: 24329153
[TBL] [Abstract][Full Text] [Related]
2. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
Jakubowiak A
Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
[TBL] [Abstract][Full Text] [Related]
3. [The treatment of relapsed or refractory multiple myeloma].
Tsurumi H
Nihon Rinsho; 2015 Jan; 73(1):114-8. PubMed ID: 25626315
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
5. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
[TBL] [Abstract][Full Text] [Related]
8. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
Siegel DS; Vij R; Jakubowiak AJ
Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatments to improve stem cell outcome: old and new drugs.
Raab MS; Breitkreutz I; Anderson KC
Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
Kuroda J
Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.
Mohty B; El-Cheikh J; Yakoub-Agha I; Avet-Loiseau H; Moreau P; Mohty M
Leukemia; 2012 Jan; 26(1):73-85. PubMed ID: 22024721
[TBL] [Abstract][Full Text] [Related]
12. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
14. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
16. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
[TBL] [Abstract][Full Text] [Related]
17. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging treatments for multiple myeloma.
Schwartz RN; Vozniak M
J Manag Care Pharm; 2008 Sep; 14(7 Suppl):12-9. PubMed ID: 18774881
[TBL] [Abstract][Full Text] [Related]
19. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed/refractory multiple myeloma.
Kastritis E; Palumbo A; Dimopoulos MA
Semin Hematol; 2009 Apr; 46(2):143-57. PubMed ID: 19389498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
